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Abstract
Background: Patients with acute pulmonary embolism (APE) with concomitant chronic
heart failure (CHF) are characterized by higher mortality rates than APE patients without
CHF. The aim of this study is to evaluate the potential impact of APE on early and long-term
prognosis in patients with CHF.
Methods: This study included 87 patients with CHF with suspected APE. Patients were
divided into two groups according to spiral computed tomography results: one group with
confirmed APE and one with excluded APE. Total and cardiovascular mortality in patients of
both groups during a 6- and 36-month follow up period was assessed. Potential risk factors for
mortality in patients with CHF in short and long-term observations were identified.
Results: APE was diagnosed in 35 patients, and excluded in the remaining 52 patients.
Total and cardiovascular 6-month mortality was higher in APE patients than in patients
without APE: 34.3% and 28.5% vs. 13.4% and 11.5%, p = 0.02, p = 0.02, respectively. In
6-month follow-up the only independent risk factor for mortality was the presence of APE
(HR = 2.7, 95% CI 1.1–24.4, p = 0.04). However, in the 36-month follow-up APE had no
effect on mortality.
Conclusions: Patients with CHF and acute episode of PE are characterized by a higher
6-month total and cardiovascular mortality rate following discharge from hospital compared to
patients hospitalized due to acute CHF decompensation. Moreover, recent episode of PE in
patients with CHF is an independent risk factor for early mortality in a 6-month follow-up.
(Cardiol J 2012; 19, 6: 625–631)
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Introduction
Chronic heart failure (CHF) is a known and
significant risk factor for acute pulmonary embo-
lism (APE). Moreover, patients with APE and co-
existing CHF are characterized by a higher mor-
tality rate than APE patients without CHF [1]. In
large PE registries, such as ICOPER registry,
CHF was observed in 10.5% of patients with APE
and was found to be an independent mortality risk
factor with a hazard ratio (HR) of 2.4 [2]. Similar
symptomatology of both diseases still hinders dia-
gnosis of APE and the implementation of an appro-
priate treatment. In patients with advanced CHF,
prevalence of APE increases and significantly in-
fluences the length of hospitalization, frequency of
re-hospitalization or frequency of early death [3, 4].
In the available literature, there are few reports
evaluating the influence of APE on the survival of
patients with CHF.
The aim of this study was a diagnostic evalua-
tion of the influence of past APE on the early and
delayed survival of patients with CHF.
Methods
Patient population
A prospective study included 87 consecutive
patients with CHF admitted to hospital due to
sudden resting dyspnoea. The suspicion of APE
was determined additionally based on the
intermediate clinical probability according to the
Wells scale, positive result of D-dimer > 0.5 µg/mL
assay measured with immunoturbobidimetric
method LIATEST, and a maximal velocity of tri-
cuspid valve regurgitation (TR) > 2.8 m/s. Etio-
logy of CHF in both studied groups is shown in
Table 1.
This study was approved by the Regional Bio-
ethics Committee, and all patients provided in-
formed consent.
Patients were divided into two groups accord-
ing to the results of spiral computed tomography
(sCT) of the thorax and compression ultrasound
(CUS) of lower extremities veins. Pulmonary em-
bolism was diagnosed when at least segmental
thromboemboli were visualized. Six- and 36-month
total mortality and cardiovascular (CV) mortality
were evaluated. Analyzis of CV mortality included:
myocardial infarction, sudden cardiac death, APE,
decompensated CHF and cerebral stroke; whereas
the analysis of total mortality comprised the remain-
ing causes including the neoplastic disease. Data on
patients deaths were obtained from the regional De-
partment of National Health Fund. Also, potential
and independent risk factors for the death of pa-
tients with CHF under short- and long-term obser-
vations were determined.
Definitions
CHF was diagnozed based on a clinical findings
according to Framingham criteria and earlier med-
ical records. APE was recognized when at least one
filling defect at sCT was visualized in at least seg-
mental arteries. APE was excluded in the case of
a negative sCT result and a negative CUS result.
CUS was carried out in 4 points within femoral and
popliteal veins. The total collapse of a vessel wall
excluded the presence of thrombosis; whereas,
a lack of total collapse of the vessel confirmed the
presence of proximal thrombosis [5, 6]. Renal fail-
ure was diagnozed when serum creatinine level was
found to be ≥ 1.3 mg/dL on admission. Hyponatre-
mia was diagnozed when sodium (Na) level in blood
serum was < 136 mmol/L on admission.
Patients with acute coronary syndromes with-
in the last 14 days and patients without diagnozed
CHF were not included in this study.
Echocardiographic examination
For all patients, a standard echocardiographic
examination was performed with a 2.5 MHz trans-
Table 1. Etiology of chronic heart failure (CHF) in both studied groups.
Causes of CHF (%) All patients (n = 87) PE+ (n = 35) PE– (n = 52) P
Coronary artery disease* 27 (32.9) 9 (25.7) 18 (34.6) 0.37
Hypertension 33 (37.9) 15 (42.8) 18 (34.6) 0.43
Atrial fibrillation 10 (11.5) 5 (14.2) 5 (9.6) 0.50
Valvular heart disease 7 (8.0) 4 (11.4) 3 (5.7) 0.34
Dilated cardiomyopathy 10 (11.5) 2 (5.7) 8 ( 15.3) 0.16
HFPEF (LVEF > 45%) 49 (56.3) 22 (62.8) 27 (52.0) 0.31
*History of myocardial infarction, percutaneous transluminal coronary angioplasty and coronary artery bypass grafting, PE — pulmonary embolism;
HEPEF — heart failure with preserved ejection fraction, LVEF – left ventricular ejection fraction
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ducer (System 5, Vingmed, General Electric). In
parasternal long-axis projection, left ventricular
end-diastolic dimension (LVEDD) and right ventri-
cular end-diastolic dimension (RVEDD) were mea-
sured. In apical 4-chamber projection, maximal  tri-
cuspid regurgitation pressure gradient (TRPG) and
left ventricular ejection fraction (LVEF) employing
the simplified Simpson method were evaluated
[7, 8]. With the use of one-dimensional M-mode exa-
mination, a tricuspid annular plane systolic excur-
sion (TAPSE) was measured [9].
Treatment
Patients with CHF received standard therapy
for heart failure: angiotensin converting enzyme
(ACE)-inhibitor or AT1 receptor antagonist, beta-
-receptors antagonist, diuretics or spironolactone. In
some patients with persistent atrial fibrillation digo-
xin was used. Patients with confirmed APE were
treated with intravenous infusion of non-fractionat-
ed heparin in a therapeutic dose under the control of
activated partial thromboplastin time 50–70 s for at
least 5 days; and in all patients oral anticoagulant was
included in their treatment under the control of nor-
malized prothrombin time (INR) of 2.0–3.0 value.
Non-fractionated heparin was discontinued after
2 days INR > 2. All patients with confirmed APE
were discharged from hospital on anticoagulant treat-
ment recommended for at least 3 months.
Statistical analysis
For comparison, Student’s t test or Mann-Whit-
ney test were used depending on the distribution of
variables. Data on normal distribution were present-
ed as a mean with standard deviation (SD). Variables
not meeting the requirements of a normal distribu-
tion were presented as a median with a range of va-
lues; the c2 test was used for comparison of variables
in multi-partition tables. To identify predictors of
mortality, Cox proportional hazards regression ana-
lysis was performed. Continuous variables were
analyzed in the analysis of dichotomous form accor-
ding to significant cut-off points. For multivariate
analysis, only those parameters were included which
demonstrated statistical significance (p < 0.05) in
univariate analysis. Survival time of patients was
determined by the Kaplan-Meier curve; the log-rank
test was used for comparison. Statistical analyzis was
carried out with the use of Statistica 6 software.
Results
The study comprized 87 consecutive patients
with CHF admitted to hospital due to episode of
sudden dyspnoea at rest, with clinically suspected
APE of at least a moderate clinical probability
according to the Wells’ probability scale [10], posi-
tive result of D-dimer > 0.5 µg/mL and TR > 2.8 m/s.
Eventually, APE was tomographically diagnosed in
35 patients, while in the remaining 52 subjects APE
was excluded. Demographic and clinical characte-
ristics of patients in both groups are presented in
Table 2.
The mean age of the patients in both groups,
with confirmed APE and without APE, was similar.
Incidence of concomitant diseases, such as: arterial
hypertension, history of myocardial infarction, atrial
fibrillation, chronic obstructive pulmonary disease
was also similar for both groups.
CHF of NYHA class IV, III and II ware present
in a similar percentage in both studied groups. How-
ever, at echocardiographic examination, patients
with confirmed APE were characterized by lower
LVDD, higher RVDD, decreased RV contractility
assessed with TAPSE than patients with excluded
APE. However, patients in both groups did not dif-
fer in TRPG value and LVEF. Plasma creatinine
level was significantly higher in the APE group, al-
though renal failure was present with a similar fre-
quency in both groups, 43.3% of APE patients and
in 31.2% of patients without APE, respectively
(p = 0.27). Venous thromboembolism (VTE) risk
factors, the presence of the neoplastic disease, a his-
tory of surgery within the past month and a posi-
tive history of APE or venous thrombosis in both
examined groups were similar. Treatment of CHF
in both groups did not differ significantly with re-
gard to the frequency of beta-receptors antagonists
use, ACE inhibitors, AT1 receptors antagonists,
diuretics, spironolactone and cardiac glycosides and
is shown in Table 3. Obviously patients with dia-
gnozed APE were anticoagulated and at discharge
85% of them were treated with oral anticoagulants
according to INR, and remaining 15% were treated
with weight adjusted dose of low molecular weight
heparin. Patients without APE received an oral
anticoagulant at discharge in 53% of cases. The
presence of atrial fibrillation was the main indica-
tion for long term anticoagulant prophylaxis in these
patients.
During a 6-month observation period, total
mortality was found to be higher in a group of pa-
tients with confirmed APE when compared to pa-
tients without APE and was 34.4% vs. 13.4%, re-
spectively (p = 0.02). However, at 36-month fol-
low-up, total mortality did not differ statistically
between both groups, but the tendency for a high-
er mortality rate was observed in patients with
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APE, which was 51.4% vs. 36.5%, respectively
(p = 0.11) (Fig. 1). Interestingly, in a 6-month ob-
servation, CV mortality was higher in patients with
APE than in the group without APE and was 28.5%
vs. 11.5%, respectively (p = 0.02); whereas in
Table 2. Demographic and clinical characteristics of patients of both groups.
Variables All patients (n = 87) PE+ (n = 35) PE– (n = 52) P
Age (years) (SD) 74.3 ± 11.3 75.7 ± 10.9 73.4 ± 11.5 0.35
Female gender (%) 51.7 54.3 50.0 0.17
Hypertension (%) 63.2 62.8 63.4 0.43
Prior MI (%) 31 22.8 36.5 0.17
Diabetes mellitus (%) 25.3 31.4 19.2 0.19
Atrial fibrillation (%) 43.7 37.1 48.0 0.31
COPD (%) 11.5 6.9 16.6 0.21
NYHA class IV (%) 29.9 22.9 34.6 0.24
NYHA class III (%) 59.7 68.6 53.9 0.16
NYHA class II (%) 10.4 8.5 11.5 0.65
LVEDD [cm] 5.35 ± 10 5.09 ± 1.0 5.51 ± 0.9 0.05
LVEDD > 5.6 cm (%) 39.0 31.4 44.2 0.23
RVEDD [cm] 3.3 ± 0.5 3.4 ± 0.4 3.2 ± 0.6 0.04
RVEDD > 3.0 cm (%) 77.0 88.5 67.3 0.02
TRPG [mm Hg] 47 ± 14 50 ± 14 45 ± 13 0.10
TRPG > 3.4 m/s (%) 43.7 48.5 38.4 0.34
LVEF (%) 47.8 ± 15 50 ± 13 46 ± 16 0.13
LVEF < 40% 34.5 25.7 40.3 0.15
TAPSE [cm] 1.5 ± 0.4 1.4 ± 0.3 1.6 ± 0.4 < 0.0001
Serum sodium [mmol/L] 139.2 ± 5.2 138.7 ± 0.6 139.5 ± 4.5 0.54
Serum sodium < 136 mmol/L (%) 27.3 37.9 21.2 0.11
Serum creatinine [mg/dL] 1.1 (0.6–3.4) 1.2 (0.6–3.4) 1.0 (0.6–2.2) 0.03
Serum creatinine ≥ 1.3 mg/dL (%) 35.9 43.3 31.2 0.27
Cancer (%) 11.5 11.4 11.5 0.98
Surgery within 1-month (%) 2.3 5.7 0 0.08
Previous VTE (%) 11.5 11.4 11.5 0.98
PE — pulmonary embolism; MI — myocardial infarction; COPD — obstructive pulmonary disease; NYHA — New York Heart Association; LVEDD — left
ventricular end-diastolic diameter; RVEDD — right ventricular end-diastolic diameter; TRPG — tricuspid regurgitation pressure gradient; LVEF — left
ventricular ejection fraction; TAPSE — tricuspid annular peak systolic excursion; VTE — venous thromboembolism
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Figure 1. Survival estimated using Kaplan-Meier curves in
patients with and without acute pulmonary embolism (APE)
in a 36-month observation in analyzis of total mortality.
Table 3. Treatment of chronic heart failure in
both groups.
Variables PE+ PE– P
(n = 35)  (n = 52)
Beta-blockers 94% 93% 0.83
ACEI/AT1 receptors 73% 87% 0.10
antagonists
Diuretics 60% 71% 0.32
Spironolactone 60% 65% 0.67
Cardiac glycosides 7% 14% 0.34
Oral anticoagulant/LMWH 85/15% 53/0% 0.003
PE — pulmonary embolism; ACEI — angiotensin converting enzyme
inhibitors; LMWH — low molecular weight heparin
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a 36-month follow-up period, no such difference was
observed (40.0% vs. 34.6%, p = 0.36) (Fig. 2, Table 4).
In order to assess independent risk factors for
the total mortality of patients with CHF, univariate
and multivariate analyses of Cox proportional haz-
ards regression analysis were performed. Potential
significance of clinical, echocardiographic and lab-
oratory parameters was analyzed. In a 6-month ob-
servation period, mortality predictors of included:
presence of APE: HR = 3.2 (95% CI 1.3–12.2),
p = 0.02, hyponatremia (NaCl < 136 mmol/L):
HR = 2,8 (95% CI 1.3–18.5), p = 0.03 and renal
failure (serum creatinine ≥ 1.3 mg/dL): HR = 2.6
(95% CI 1.2–17.4), p = 0.04 (Table 5).
However, in a multivariate analysis, the only
independent risk factor for death in a 6-month ob-
servation period was the presence of APE with
HR = 2.7 (95% CI 1.1–24.4), p = 0.04, while hypona-
tremia and renal failure were not independent
mortality predictors (Table 6). In a long-term
36-month follow-up period, not found the potential
risk factor for death of patients with CHF.
Discussion
Decompensated chronic heart failure is a fre-
quent cause of CV hospitalization [11–15].
Recent registries demonstrated significant in-
hospital mortality of CHF patients of 4–7% [16, 17].
It is generally accepted that patients with CHF are
characterized by an increased risk of VTE. In vari-
ous studies, the incidence of APE or deep vein
thrombosis  in the population of patients hospital-
ized due to CHF ranged from 4% to 14% [18–20].
In another study, the incidence of APE in a group
of patients with CHF was 9.1% despite adequate use
Table 6. Multivariate predictors of death of pa-
tients with chronic heart failure at 6 months.
Variables HR (95% CI) P
Sodium serum level 2.2 (0.9–15.9) 0.10
< 136 mmol/L
Creatinine serum level 2.2 (0.8–15.7) 0.11
≥ 1.3 mg/dL
Acute pulmonary 2.7 (1.1–24.4) 0.04
embolism
HR — hazard ratio; CI — confidence interval
Table 5. Univariate predictors of death of pa-
tients with chronic heart failure at 6 months.
Variables HR (95% CI) P
Sodium serum level 2.8 (1.3–18.5) 0.03
< 136 mmol/L
Creatinine serum level 2.6 (1.2–17.4) 0.04
≥ 1.3 mg/dL
Acute pulmonary 3.2 (1.3–12.2) 0.02
embolism
HR — hazard ratio; CI — confidence interval
Table 4. Total and cardiovascular mortality of patients of both groups.
Variables All patients (n = 87) PE+ (n = 35) PE– (n = 52) P
Total mortality 6-month (%) 21.9 34.3 13.4 0.02
Total mortality 36-months (%) 42.5 51.4 36.5 0.11
Cardiovascular mortality 6-months (%) 18.4 28.5 11.5 0.02
Cardiovascular mortality 36-months (%) 36.8 40.0 34.6 0.46
PE — pulmonary embolism
Figure 2. Survival estimated using Kaplan-Meier curves
in patients with and without acute pulmonary embo-
lism (APE) in a 36-month observation in analyzis of car-
diovascular mortality.
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of antithrombotic prophylaxis in 2/3 of patients [3].
In the ICOPER registry with 2554 patients, APE
accompanying CHF was diagnosed in 10.5% of pa-
tients [2]. The presence of CHF in patients with
APE worsens their prognosis and is an independent
risk factor for death [1, 2]. Darze et al. [4] observed
that APE worsens the prognosis or increases the
frequency of hospitalization in a 3-month observa-
tion in patients with CHF. In our study, we com-
pared patients with CHF and concomitant APE with
patients with CHF and excluded APE in short- and
long-term observations. In a 6-month observation,
the total and CV mortality of patients with APE was
significantly higher compared to patients without
APE: 34.4% vs. 13.4% (p = 0.02) and 28.5%
vs. 11.5% (p = 0.02), respectively. However, the
36-month total and CV mortality for both studied
groups was similar. It partly confirms the results
of the Darze et al. study [4], which showed a trend
towards a higher 3-month mortality rate for patients
with CHF with confirmed APE compared to patients
with CHF. In that study, a combination of 3-month
mortality with 3-month re-hospitalization showed
a significant predominance of adverse events in
patients with APE by 72.2% vs. 43.5%, respective-
ly (p = 0.02) [4]. In our study, total and CV mortal-
ity was evaluated and demonstrated a significant
difference in frequency against patients with con-
firmed APE in a 6-month observation. To our
knowledge, this is the first study which compares
patients with CHF with confirmed APE during hos-
pitalization with patients with CHF and excluded
APE. In the Darze et al. study [4], a group of
18 patients with confirmed APE was compared with
a group of 180 patients of whom only in 18 cases APE
was excluded based on a negative result of sCT or
pulmonary scyntygraphy. In that study, an indepen-
dent factor for death or 3-month re-hospitalization
was a history of APE (OR = 4.0, 95% CI 1.1–15.1,
p = 0.038). That study confirms our results that an
independent risk factor for death of patients with
CHF is a history of APE in a 6-month observation
(HR = 2.7, 95% CI 1.1–24.4, p = 0.04).
Persistent higher mortality of patients with
CHF and APE during a 6-month period following
discharge from hospital compared to patients with-
out APE may be explained by its adverse influence
on the clinical course of patients with CHF. A sud-
den increase of pulmonary pressure observed dur-
ing APE results in pressure and volume overload
of the RV. In previous studies, it was reported that
prognosis for patients after APE depends mostly on
RV efficiency and recurrences of APE. In our study,
all patients with APE were at a low risk of early
death and received prophylactic treatment with an
oral anticoagulant in 85% of cases or low molecular
weight heparin in 15% of cases. Despite an appro-
priate anticoagulant therapy, patients with a histo-
ry of APE were characterized by a higher total and
CV mortality rate than patients without APE in
a 6-month observation period following discharge
from hospital. Similar risk factors for VTE and acute
coronary syndrome have been discussed recently.
Can similar mechanisms of venous and arterial
thrombosis cause an increase in the frequency of
APE events and an increase in thromboembolic
complications frequency after APE? Such a thesis
is quite bold at present.
If the results of our study, indicating that APE
is an independent factor for poor prognosis of pa-
tients with CHF, are confirmed in further analyzes,
we should consider a simple and efficient model of
APE diagnosis in patients with CHF and a more
efficient secondary anticoagulant prophylaxis fol-
lowing discharge from hospital.
Limitations of the study
The main limitation of our study is the fact that
this one-center observation which was carried out
with a relatively small group of patients.
Conclusions
Patients with CHF and acute episode of pulmo-
nary embolism are characterized by a higher
6-month total and CV mortality rate following dis-
charge from hospital compared to patients hospi-
talized due to acute CHF decompensation. More-
over, recent episode of PE in patients with CHF is
an independent risk factor for early mortality in
a 6-month follow-up; whereas in a 36-month obser-
vation, past APE had no influence on mortality.
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